Stockscreener 앱 받기
27.67
2.07%
0.56
시간 외 거래:
27.60
-0.07
-0.25%
전일 마감가:
$27.11
열려 있는:
$26.29
하루 거래량:
1.98M
Relative Volume:
0.95
시가총액:
$2.85B
수익:
$139.74M
순이익/손실:
$-79.99M
주가수익비율:
-27.24
EPS:
-1.0157
순현금흐름:
$-360.05M
1주 성능:
-6.30%
1개월 성능:
-9.84%
6개월 성능:
+24.58%
1년 성능:
+60.69%
1일 변동 폭
$26.04
$27.78
1주일 범위
$25.87
$29.34
52주 변동 폭
$15.35
$36.44
빔 테라퓨틱스 Stock (BEAM) Company Profile
명칭
Beam Therapeutics Inc
전화
857-327-8775
주소
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
27.67 | 2.79B | 139.74M | -79.99M | -360.05M | -1.0157 |
VRTX
Vertex Pharmaceuticals Inc
|
433.54 | 109.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
642.59 | 68.12B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
816.22 | 50.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
300.51 | 39.85B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.73 | 31.96B | 742.00K | -1.37B | -1.07B | -7.0731 |
빔 테라퓨틱스 Stock (BEAM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-20 | 개시 | Canaccord Genuity | Buy |
| 2025-10-09 | 개시 | Jefferies | Buy |
| 2025-03-28 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-03-10 | 업그레이드 | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-07-23 | 개시 | H.C. Wainwright | Buy |
| 2024-01-29 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-12-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-10-20 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2023-02-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-12-20 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | 개시 | Citigroup | Buy |
| 2022-06-17 | 개시 | BMO Capital Markets | Market Perform |
| 2022-04-28 | 개시 | Credit Suisse | Neutral |
| 2022-01-05 | 개시 | Guggenheim | Buy |
| 2021-10-19 | 개시 | SVB Leerink | Outperform |
| 2021-09-24 | 재개 | Stifel | Buy |
| 2021-09-10 | 개시 | BofA Securities | Buy |
| 2021-05-11 | 개시 | Redburn | Buy |
| 2021-05-04 | 개시 | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2021-02-16 | 개시 | Wells Fargo | Overweight |
| 2021-01-29 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-01-06 | 개시 | Stifel | Hold |
| 2020-08-05 | 개시 | William Blair | Outperform |
| 2020-03-02 | 개시 | Barclays | Overweight |
| 2020-03-02 | 개시 | JP Morgan | Overweight |
| 2020-03-02 | 개시 | Jefferies | Buy |
| 2020-03-02 | 개시 | Wedbush | Outperform |
모두보기
빔 테라퓨틱스 주식(BEAM)의 최신 뉴스
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy - Investing.com
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy By Investing.com - Investing.com Canada
Beam Therapeutics eyes sickle cell BLA as Alpha-1 gene-editing program advances - MSN
Beam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program Advances - Yahoo Finance
BEAM: Lead gene editing programs advance toward approval with strong efficacy, safety, and payer value - TradingView
Beam Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Two Programs That Could Make or Break Beam Therapeutics Inc (BEAM) Stock - Insider Monkey
In Vivo Gene Editing Market is expected to Hit US$ 37.75 Billion - openPR.com
10 Best Gene Therapy Stocks to Buy in 2026 - Insider Monkey
Beam Therapeutics (BEAM) Is Down 12.0% After Narrowing Losses And Positive BEAM-302 Data Update – Has The Bull Case Changed? - Sahm
Beam Therapeutics Data Puts BEAM 302 And AAT Disease In Focus - Yahoo Finance
Beam Therapeutics (BEAM) Advances Phase 1/2 Trial for AAT Deficiency - GuruFocus
Verve Therapeutics : VERV - 24/7 Wall St.
Beam Therapeutics presents AATD gene therapy trial data at ATS By Investing.com - Investing.com Australia
Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference - The Manila Times
One-time gene-editing AATD therapy BEAM-302 seeks accelerated FDA path - Stock Titan
Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy? - Yahoo Finance
BEAM Stock's Gains Fade Despite Promising Data Rare Liver Disease Treatment Data - Stocktwits
Beam Therapeutics Inc (BEAM) Stock Price, Quote, News & History - Benzinga
HC Wainwright Expects Lower Earnings for Beam Therapeutics - MarketBeat
BEAM News Today | Why did Beam Therapeutics stock go up today? - MarketBeat
BEAM's Q1 loss wider than expected, revenues beat estimates - MSN
Beam Therapeutics (NASDAQ:BEAM) Stock Price Down 8%Should You Sell? - MarketBeat
H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80 - Moomoo
Beam Therapeutics Stock Stumbles After Post-Rally Shakeout - TipRanks
BEAM Maintained by Bernstein -- Price Target Lowered to $39.00 - GuruFocus
AlphaDetect Partners with Beam Therapeutics to Enhance Detection Efforts - Intellectia AI
Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1 - ChartMill
Beam Therapeutics: Base Editing Is Moving From Platform Story To Regulatory Asset Story - Seeking Alpha
Bernstein Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Cuts Target Price to $39 - Moomoo
Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference - The Manila Times
Free genetic tests to spot underdiagnosed Alpha-1 lung and liver risk - Stock Titan
Beam Therapeutics to present sickle cell therapy data at EHA - Investing.com India
Beam Therapeutics to present sickle cell therapy data at EHA By Investing.com - Investing.com South Africa
Beam Therapeutics to Present Positive Biomarker Data from BEACON Trial of Ristoglogene Autogetemcel for Sickle Cell Disease at EHA2026 - Quiver Quantitative
Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026 - The Manila Times
Beam Therapeutics to Present Updated Biomarker Data from - GlobeNewswire
(BEAM) Volatility Zones as Tactical Triggers - Stock Traders Daily
Analysts Are Upgrading Beam Therapeutics Inc. (NASDAQ:BEAM) After Its Latest Results - Moomoo
Earnings Update: Beam Therapeutics Inc. (NASDAQ:BEAM) Just Reported And Analysts Are Boosting Their Estimates - Yahoo Finance
Vanguard Group Inc. Sells 57,310 Shares of Beam Therapeutics Inc. $BEAM - MarketBeat
Wedbush Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $65 - Moomoo
Evercore Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Raises Target Price to $45 - Moomoo
BEAM's Q1 Loss Wider Than Expected, Revenues Beat Estimates - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Beam Therapeutics (BEAM) - The Globe and Mail
Beam Therapeutics edges higher after new sickle cell therapy results - MSN
MSN Money - MSN
빔 테라퓨틱스 (BEAM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
빔 테라퓨틱스 주식 (BEAM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Evans John M. | CEO |
Apr 01 '26 |
Sale |
24.58 |
30,078 |
739,317 |
1,047,205 |
| Simon Amy | Chief Medical Officer |
Apr 01 '26 |
Sale |
24.58 |
6,700 |
164,686 |
102,735 |
| Cavanagh Bethany J | SVP, Finance and Treasurer |
Apr 01 '26 |
Sale |
24.58 |
3,242 |
79,688 |
51,171 |
| Bellon Christine | Chief Legal Officer |
Apr 01 '26 |
Sale |
24.58 |
5,956 |
146,398 |
109,711 |
| Ciaramella Giuseppe | President |
Apr 01 '26 |
Sale |
24.58 |
11,810 |
290,290 |
218,406 |
| Evans John M. | CEO |
Mar 30 '26 |
Option Exercise |
0.67 |
25,000 |
16,750 |
1,011,667 |
| Evans John M. | CEO |
Mar 31 '26 |
Option Exercise |
0.67 |
25,000 |
16,750 |
1,011,667 |
| Evans John M. | CEO |
Mar 31 '26 |
Sale |
22.76 |
25,000 |
569,085 |
986,667 |
| Evans John M. | CEO |
Mar 30 '26 |
Sale |
22.37 |
25,000 |
559,230 |
986,667 |
4.72%
0.63%
자본화:
|
볼륨(24시간):